Entry Detail



General Information

Database ID:exR0092892
RNA Name:hsa-let-7a-5p
RNA Type:miRNA
Chromosome:chr9
Starnd:+
Coordinate:
Start Site(bp):94175962End Site(bp):94175983
External Links:hsa-let-7a-5p



Disease Information

Disease Name:Benign Ovarian Disease
Disease Category:Urogenital Diseases and Pregnancy Complications
MeSH ID:D010049
Type:Diseases Category/Female Urogenital Diseases and Pregnancy Complications
Alias:Ovarian Diseases//Disease, Ovarian//Diseases, Ovarian//Ovarian Disease



Expression Detail

GEO ID:GSE106817
Description:Integrated extracellular microRNA profiling for ovarian cancer screening
Experimental Design:Cancer vs Control
Case Disease Type:Benign Ovarian Disease
Case Disease SubType:NA
Case Sample:Benign Ovarian Disease
Control Sample:Non-Cancer
Number of Case:29
Number of Control:2759
Number of Samples:2788





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
HMGA1
chr6
34236873
34246231
+
PDPR
chr16
70113626
70162537
+
ERO1A
chr14
52639915
52695900
-
UBE2G2
chr21
44768580
44801826
-
CD82
chr11
44564427
44620358
+
YOD1
chr1
207043849
207052980
-
HMGA2
chr12
65824131
65966295
+
MYL12A
chr18
3247481
3256236
+
CTPS2
chrX
16587999
16712936
-
MARCKSL1
chr1
32333839
32336233
-
AGRN
chr1
1020120
1056118
+
STK4
chr20
44966479
45080021
+
BRD4
chr19
15235519
15332545
-
C1orf43
chr1
154206696
154220637
-
PLD3
chr19
40348456
40380439
+
BACH1
chr21
29194071
29630751
+
PPARA
chr22
46150521
46243756
+
WDR83OS
chr19
12668073
12669415
-
BCAM
chr19
44809071
44821421
+
IGF2BP1
chr17
48997385
49056145
+
SNRPC
chr6
34757505
34773857
+
COIL
chr17
56938199
56961050
-
RANBP2
chr2
108719482
108785809
+
ZNF576
chr19
43596392
43601157
+
BLOC1S6
chr15
45587214
45615945
+
ARHGAP28
chr18
6729718
6915716
+
TRIM65
chr17
75880335
75896951
-
NHLRC3
chr13
39038306
39050109
+
TAF4
chr20
61953469
62065810
-
IGDCC3
chr15
65327127
65378002
-
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0000247
chr10
74474868
74475660
+
hsa_circ_0000987
chr2
30748452
30756180
+
hsa_circ_0000246
chr10
74468040
74475660
+
hsa_circ_0000018
chr1
15860731
15863309
+
hsa_circ_0000038
chr1
28800065
28802803
+
hsa_circ_0000799
chr17
65941524
65972074
+
hsa_circ_0001164
chr20
45891031
45923523
-
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC006064.5
chr12
6510275
6510522
+
AC074117.1
chr2
27356246
27367622
+
AC109460.3
chr16
28974804
28990775
+
AC124045.1
chr3
44667412
44669364
+
AL359924.1
chr1
237862175
237928321
+
AP000766.1
chr11
107312132
107316271
-
ARHGAP27P1-BPTFP1-KPNA2P3
chr17
64749663
64781707
-
KCNQ1OT1
chr11
2608328
2699994
-
LINC00265
chr7
39733430
39793092
+
LINC02381
chr12
54126082
54147485
+
MIRLET7BHG
chr22
46053869
46113928
+
NEAT1
chr11
65422774
65445540
+
NUTM2A-AS1
chr10
87201647
87342612
-
SNHG16
chr17
76557764
76565348
+
SNHG4
chr5
139274102
139284899
+
TMPO-AS1
chr12
98512973
98516422
-
XIST
chrX
73820649
73852723
-
ZNF436-AS1
chr1
23368997
23371839
+
AD000090.1
chr19
35557956
35581954
+
LINC01744
chr1
232727251
232751299
-
Display:



Experiment Detail

GEO ID:GSE106817
Sample Source:Blood
Source Fraction:Serum
Platform:GPL21263
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:2535
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).
RNA library preparation protocol:miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.



Reference

PMID:30333487
Title:Integrated extracellular microRNA profiling for ovarian cancer screening
Author:Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T
Journal:Nat Commun. 2018 Oct 17;9(1):4319.
Description:to develop an optimal detection method, we use microarrays to obtain comprehensive miRNA profiles from 4046 serum samples, including 428 patients with ovarian tumors.